Immunovia is hosting a webcast with the opportunity to learn more about the positive clinical validation of its next-generation pancreatic cancer test

LUND, Sweden, December 16, 2024 /PRNewswire/ — Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, announced positive results from the clinical validation of its next-generation pancreatic cancer test on June 13, 2019 December 9, 2024. As an addendum Immunovia will host a webcast Tuesday, December 17th at 3:00 p.m. CET.

Jeff BorcherdingCEO, Norma Alonzo PalmaPhD, VP Clinical and Medical (TASE:) Affairs and Lisa Ford (NYSE:)PhD, Laboratory Director will present further details on the results and implications of the study. Dr. Aimee LucasChief physician for gastroenterology and hepatology Mount Sinai and professor of Medicine Icahn School of Medicinewill participate in the webcast to share his perspective on the study results. The webcast will be held in English and will offer participants the opportunity to ask questions. You are welcome to join in, see details below.

Link to webcast: https://link.edgepilot.com/s/e8dd2ee9/T5WEGMPm6EqzxajKwPwQbw?u=https://creo-live.creomediamanager.com/dd81645b-30e0-45e1-af83-75a059fcba71

A recording of the presentation is available at Immunovia Website.

For further information please contact:
Karin Almqvist Liwendahl
CFO
karin.almqvist.liwendahl@immunovia.com

Immunovia short

Immunovia AB is a diagnostics company whose mission is to increase the survival rates of patients with pancreatic cancer through early detection. Immunovia focuses on developing and commercializing simple blood-based tests to detect proteins and antibodies that indicate that a high-risk person has pancreatic cancer.

Immunovia partners and collaborates with healthcare providers, leading experts and patient advocacy groups to make its test available to people at increased risk of pancreatic cancer.

USA is the world’s largest pancreatic cancer detection market. The company estimates that in the USA1.8 million people are at high risk of pancreatic cancer and could benefit from annual surveillance testing.

Immunovia Shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, visit www.immunovia.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/immunovia-ab/r/immunovia-to-host-a-webcast-with-the-opportunity-to-learn-more-about-the-positive-clinical-validatio,c4082507

The following files are available for download: